Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $749.0K | $4.1M | $10.9M | $19.6M |
| Cost of revenue | $19.0K | $23.0K | $23.0K | $163.0K | $282.0K | $10.7M | $6.8M | $9.0M |
| Gross profit | −$19.0K | −$23.0K | −$23.0K | −$163.0K | $467.0K | −$6.6M | $4.0M | $10.6M |
| Gross margin | — | — | — | — | 62.3% | -161.4% | 37.2% | 54.2% |
| R&D | $20.9M | $14.4M | $9.8M | $9.9M | $13.5M | $6.2M | $3.3M | $2.2M |
| Operating income | −$29.7M | −$26.8M | −$19.5M | −$18.9M | −$49.1M | −$71.0M | −$41.4M | −$19.9M |
| EBITDA | −$29.7M | −$26.5M | −$19.5M | −$18.6M | −$48.5M | −$64.9M | −$25.4M | −$12.7M |
| Net income | −$28.7M | −$28.3M | −$19.8M | −$18.4M | −$54.7M | −$76.6M | −$25.4M | −$14.5M |
| Net margin | — | — | — | — | -7301.2% | -1867.5% | -233.5% | -73.8% |
| EPS (diluted) | -2033.18 | -1829.61 | -1152.82 | -746.20 | -1291.56 | -63115.49 | -58.79 | -6.71 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $66M | $1.70 | $1.70–$1.70 | 1 |
| 2027 | $96M | $3.47 | $3.47–$3.47 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds AGRX.
No tracked institution reports a position in AGRX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-04-11 | 1-for-50reverse |
| 2022-04-27 | 1-for-40reverse |
No one on the platform has traded AGRX yet.
| $0 |
| — |
| FLWPFThe Flowr Corporation | $0.00 | +0.00% | $4265 | — |
| GHSIGuardion Health Sciences, Inc. | $3.25 | +0.93% | $4M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× sales vs its 0.6× historical median P/S.
Fair value ≈ $13.66 · price $1.51 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ICU lots of catalysts incoming. Q1 quarterly tomorrow after the bell- FDA SAVE update soon. ( FDA dropped requirement from 300-50) Revenue growing- One big pediatric hospital named the Seastar SCD the new SOC- 6 breakthrough device destinations- float 4 million- about 7ish million cash-----dyor $ALLR $APVO $AMC $AGRX TAM billions SCD pediatric FDA HDE approved Phase III adult trial has a TAM or 4 billion plus. ADD TO WATCH LIST- THIS IS MY TOP HOLDING- I THINK ITS A BILLION DOLLAR COMPANY IS 2-3 YEARS device prevents organ damage- saves lives- less time in hospital- saves insurance companies money DYOR
View on StockTwits ↗@sheza65 Very nice congrats … unfortunately nothing like that on my end with this one, much smaller gains, though that reminds me of my $AGRX days, at least the good part and the early days of $NLST when it hit $10 … it’s always great when these sub $1 move like this … I also think it an F at the end carries more weight 😆
View on StockTwits ↗$RMSG break that $2.10 again and we are off to $2.75. Im adding here. Appears to be a big green candle in the works. PT is $3.50 by AH. $ACON $ADIL $AGRX @Jelaw178isback @JokerTrades
View on StockTwits ↗$AGRX Getting my powder READY for the drop!!!! https://m.youtube.com/watch?v=u0qcDZIDB-I&t=1121s
View on StockTwits ↗$SAFX I agree, wait until 7-7:30pm or so-the shorts will panic. This can go as high as $AGRX did today and more.
View on StockTwits ↗$SPRY Best comparison to this company is/was $AGRX. AGRX had a one-of-a-kind low dose estrogen patch that was especially useful for ladies who wanted the convenience of a patch if they don't want to be constantly forgetting to take the pill. However, sales were routinely low despite benefits of the patch. The company only had this single product. It was ultimately sold to another company for pennies on the dollar. Fast foward to SPRY's Neffy. Has clear advantages to the EpiPen. However, sales are bad and adoption is low. They have no other products to sell. I believe SPRY will ultimately go the way AGRX went.
View on StockTwits ↗$AGRX Loading here, and so is someone else ;)
View on StockTwits ↗@Super_Marioo you made me a bunch of money on $MIST back in 2020. Then I lost it all on $AGRX 🤣 Have you looked at $OTLK?
View on StockTwits ↗@Bee202 @Honduran7 Lessons learned indeed... I'm in on $OTLK now I like that they are replacing a existing off label use of a drug instead of trying to bring a novel product to the market like $AGRX.
View on StockTwits ↗@Honduran7 @landandlivestock lol ya $AGRX was as a real sh*t show after approval
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.